Kyverna Therapeutics Inc(KYTX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -2.94 | Insider Own | 37.02% | Shs Outstand | 61.6M | Perf Week | 4.82% |
| Market Cap | 0.35B | Forward P/E | - | EPS next Y | -12.84% | Insider Trans | - | Shs Float | 39.0M | Perf Month | -13.34% |
| Enterprise Value | 0.18B | PEG | - | EPS next Q | -0.69 | Inst Own | 49.11% | Short Float | 24.5% | Perf Quarter | -24.77% |
| Income | -0.15B | P/S | - | EPS this Y | 24.15% | Inst Trans | 3.66% | Short Ratio | 11.56 | Perf Half Y | -36.3% |
| Sales | 0.00B | P/B | 2.1 | EPS next 5Y | 10.13% | ROA | -68.4% | Short Interest | 9.54M | Perf YTD | -39.89% |
| Book/sh | 2.69 | P/C | 1.75 | EPS past 3/5Y | -75.86% -56.27% | ROE | -87.24% | 52W High | -58.67% ($13.67) | Perf Year | -16.3% |
| Cash/sh | 3.22 | P/FCF | - | Sales past 3/5Y | - | ROIC | -77.47% | 52W Low | 9.5% ($5.16) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 20.07% | Gross Margin | - | Volatility(W/M) | 6.4% 6.23% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.37 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 9.06 | EPS Q/Q | 35.37% | Profit Margin | - | RSI (14) | 40.54 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 9.06 | Sales Q/Q | - | SMA20 | -3.95% ($5.88) | Beta | 2.08 | Target Price | $30.4 |
| Payout | - | Debt/Eq | 0.2 | Earnings | 2026/8/11 | SMA50 | -18.18% ($6.91) | Rel Volume | 0.77 | Prev Close | $5.85 |
| Employees | 130 | LT Debt/Eq | 0.19 | EPS/Sales Surpr. | 7.12% - | SMA200 | -30.15% ($8.09) | Avg Volume(3M) | 0.83M | Price | $5.65 |
| IPO | 2024/2/8 | Option/Short | Yes/Yes | Trades | 6631 | Volume | 639,524 | Change | -3.42% |
🧬 Kyverna Therapeutics (KYTX) is a U.S. clinical-stage biopharmaceutical company developing next-generation cell therapies to treat autoimmune diseases. Leveraging its proprietary Smart Cell platform technology, the company is expanding CAR-T cell therapy—previously used mainly for cancer treatment—into a wide range of autoimmune disease areas, including lupus nephritis and multiple sclerosis. With its lead pipeline candidate miv-cel (KYV-101) at the core, Kyverna is committed to advancing research aimed at overcoming treatment-resistant diseases.
Over the past 1 year, on the lower side
59% below its 1-year high.
Traded less than usual. That is 77% of its average volume.
KYTX has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +24.1% this year.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
24.5% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #249 of 595 in the industry
Based on market cap of $349M.
OBIO#247 Orchestra BioMed Holdings Inc $355M PER - 
CTNM#248 Contineum Therapeutics Inc $353M PER - KYTX#249 Kyverna Therapeutics Inc $349M PER - 
NAUT#250 Nautilus Biotechnology Inc $348M PER - 
SRZN#251 Surrozen Inc $341M PER - 
FAQ
What kind of company is KYTX?
KYTX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of KYTX?
The market cap of KYTX is approximately $349M, ranking 3,471 within its sector.
What is the 52-week high and low for KYTX?
KYTX has recorded a 52-week high of $13.67 and a low of $5.16.
